Alimera Sciences (ALIM) Indicated Lower After FDA Says ILUVIEN NDA Cannot Be Approved in Present Form
Tweet Send to a Friend
Alimera Sciences (Nasdaq: ALIM) is indicated to open sharply lower after the company received an CRL from the FDA on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
